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Question 1. What is the final diagnosis?
Hypoparathyroidism in childhood is predominantly due to
congenital parathyroid agenesis or hypoplasia, associatedwith
numerous conditions, the most common one being the Di
George syndrome (approximately 70 % of children with iso-
lated hypoparathyroidism) [1]. Rare conditions may include
specific renal disturbances, such as steroid-resistant nephrotic
syndrome, kidney dysplasia, hypoplasia or aplasia in Barakat
syndrome [2]. From a nephrologist perspective, it is also
worth noting that hypomagnesemia (e.g. during chronic cy-
closporine or diuretic treatment) inhibits parathyroid hormone
secretion and can mimic hypoparathyroidism.
In the presented case, however, the coexistence of hypo-
parathyroidism, oral candidiasis, dental enamel hypoplasia
and subclinical Hashimoto's disease is strongly suggestive of
autoimmune polyglandular syndrome (APS) type 1. One of
the clinical implications of this diagnosis is the high
probability of future occurrence of adrenal insufficiency, em-
phasizing the importance of maintaining a high level of sus-
picion with the onset of symptoms such as weakness, fainting,
hypotonia or hyperkalemia. Addison’s disease would in fact
represent quite a challenge in terms of the future management
of this patient.
Question 2. What is the cause of nephrocalcinosis?
Nephrocalcinosis is defined as radiologically detectable de-
posits of calcium in the renal cortex, medulla or both. The
most severe form is a generalized calcification of kidneys seen
in classical imaging studies, including renal ultrasonography
[3]. A metabolic risk factor is identifiable in about 75 % of
children with nephrocalcinosis. In addition to hyperoxaluria
and hypercystynuria, both of which are relatively rare but
none-the-less important due to their potential morbidity, hy-
percalciuria stands out by its frequency. Three basic patho-
physiological alterations may play a role in hypercalciuria:
increased intestinal absorption, increased bone release and
decreased renal tubular reabsorption of calcium. Almost every
hypercalcemic state, such as hyperparathyroidism, Williams–
Beuren syndrome or vitamin D intoxication, can promote
nephrocalcinosis [4]. The same applies to bone disorders, in-
cluding the effect of acidosis on the release of bone buffers
and calcium. Non-hypercalcemic tubular disorders with hy-
percalciuric nephrocalcinosis are recapitulated in Fig 1. They
were ruled out in our patient.
The problem of an excessive dietetic load of calcium com-
monly arises in chronic supplementation which is the usual
therapy for disorders like hypophosphatemic rickets or hypo-
parathyroidism. The therapeutic window is often narrow be-
cause of the renal calcium leak, and it is difficult to reach the
opt imal bone–kidney trade-off . The et io logy of
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hypoparathyroidism may also predispose to the development
of nephrocalcinosis, as hypercalciuria is typically more pro-
nounced in patients with activating mutations of the calcium
sensing receptor [5]. Winner et al. described the presence of
nephrocalcinosis in the course of hypoparathyroidism of var-
ious etiologies in >40 % of patients after 20 (or more) years of
the disease [6]. In our patient, it is difficult to rule out an
additional factor, such as idiopathic hypercalciuria, as well
as autoimmune or infectious (e.g. fungal) gastrointestinal dis-
orders that are common in APS type 1 and can cause impor-
tant fluctuations in calcium absorption, narrowing even more
the therapeutic window. However, it is likely that the main
cause of nephrocalcinosis is iatrogenic and linked to the rela-
tively high doses of calcium and vitamin D supplementation,
and probably also the incident of acute hypercalcemia treated
with loop diuretics. In fact, the presented case is a typical
example of so-called refractory hypoparathyroidism, which
refers to the difficulty to achieve normocalcemia, the need
for high-dose calcium carbonate treatment and the frequent
fluctuations with episodes of transient hypercalcemia [7].
Such problematic management is typically observed in such
disorders as APS type 1, hypoparathyroidism associated with
malabsorption (especially celiac disease), and activating mu-
tations of the calcium sensing receptor (CaSR) [5]. Those
patients are understandably at a higher risk of chronic kidney
damage.
Question 3. What further treatment options are
available?
Substitution therapy in the treatment of APS is similar to that
in single endocrine organ failure. Calcium supplementation in
hypoparathyroidism is best achieved orally in three to four
divided daily doses, (20 mg/kg/day up to 1 g/day) combined
with 1,25-dihydroxyvitamin D or 1-α-hydroxyvitamin D (av-
erage 0.03 μg/kg/day). Magnesium levels should be closely
watched and supplemented usually at a dose of 50–200 mg
daily if needed [8]. It is also important to restrict the phospho-
rus in the diet. Regular check-ups of plasma and urine calcium
is recommended to adapt the dosage adequately to keep
calcemia at the lower normal range and calciuria at <4 mg/
kg/24 h. If the therapeutic goals are not achieved, the use of
thiazide diuretics can be helpful. Thiazides reduce the calcium
renal leak and calciuria, while simultaneously increasing
calcemia, thus widening the therapeutic window and allowing
calcium carbonate and vitamin D dose reduction. Moderate
hyperphosphatemia is generally not a problem provided blood
calcium levels are maintained at the lower normal range and
the calcium × phosphate product falls within safe limits.
A treatment with 12.5 mg/24 h of hydrochlorothiazide in
the presented patient significantly decreased the urine Ca/
creatinine ratio to 0.19 mg/mg. Restriction of dietetic phos-
phate and salt and supplementation with magnesium citrate
were continued. An attempt to liberalize the diet was made,
but it resulted in worsening of the hypercalciuria and an in-
crease in phosphatemia. The dose of hydrochlorothiazide had
to be increased to 25 mg/24 h (in divided doses) to maintain a
sustained hypocalciuric effect. As a result of hypokalemia
(3.68 mmol/l) secondary to hydrochlorothiazide treatment,
potassium chloride supplements were added to the therapeutic
regimen. With this additional treatment all therapeutic goals
and stable calcium parameters were achieved with ultimately
3 g of calcium carbonate and 1 μg daily of alfacalcidiol.
Despite this encouraging outcome at the present time, a
potential complication is to be expected. APS type 1 is char-
acterized by the successive onset of three cardinal symptoms:
the first to appear is usually candidiasis, the second is hypo-
parathyroidism and the third is Addison's disease with a peak
incidence in teenagers aged between 10–15 years.
Although adrenal insufficiency is treatable with substitu-
tion of hydrocortisone and analogues of endogenous mineral-
ocorticoids, the condition may lead to recurring renal salt los-
ing with serious general symptoms, such as hypotonia and
Fig. 1 Tubular disorders with
hypercalciuric nephrocalcinosis.
dRTA Distal renal tubular
acidosis,UAG urine anion gap, Sd
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loss of consciousness. Therapy with thiazide diuretics can
obviously aggravate this problem through impairment of tu-
bular salt reabsorption in the distal part of the nephron.
Adrenal insufficiency is therefore considered to be a relative
contraindication to thiazide treatment; however, the withdraw-
al of thiazides will probably result in an exacerbation of the
hypercalciuria and progression of nephrocalcinosis, which can
undoubtedly be perceived as a risk factor for progressive
chronic kidney damage. The expected fully symptomatic pre-
sentation of APS type 1 (including renal insufficiency) will
therefore make the treatment of all combined disturbances
more and more challenging. Only strict monitoring based on
repeated laboratory tests will allow correction of the primary
symptoms caused by the disease per se, without any increase
in the risk of iatrogenic disturbances, which potentially may
be even more harmful than uncorrected disorders.
Commentary
This clinical quiz highlights the importance of careful evalu-
ation of all multiorgan symptoms occurring in the described
patient to prevent further complications.
In 1980, Neufeld and Blizzard proposed the first classifica-
tion of autoimmune polyendocrine syndromes on the basis of
clinical criteria and defined four types of APS [9]. Of these
four types, polyglandular autoimmune syndrome type 1, also
known as APS1, autoimmune polyendocrinopathy–
candiasis–ectodermal dystrophy or Whitaker syndrome, is a
rare genetic disease which is autosomal recessive, inherited in
a monogenic pattern and caused by a mutation in the gene of
autoimmune regulation (AIRE) localized on the long arm of
chromosome 21 (21q22.3) [OMIM 240300] [10, 11]. It was
described for the first time in 1946 by Leonard [12]. The
prevalence of this syndrome in the Polish population was set
at 1:129 000 people. APS1 occurs in both sexes. The sug-
gested role for AIRE is to induce expression of peripheral
antigens in the thymus, thereby mediating negative selection
of autoreactive T cells and cause toleration [13]. The main
components of APS1 are hypoparathyroidism, adrenal insuf-
ficiency and candidiasis of mucous membranes (oral, anal
area, external genitals) and/or of the skin and nails. A neces-
sary condition for the diagnosis of APS1 is the simultaneous
occurrence of two of the three above-mentioned diseases.
APS1 is accompanied by other diseases with an autoimmune
origin [14–16]. The first symptom is usually candidiasis of the
oral mucosa, which occurs before the age of 5 years.
Autoimmunity in APS1 is also the responsible factor for the
CYSTATIN salivary antigen1 deficiency, which causes im-
paired protection against Candida albicans infections [17].
The first endocrinopathy is an autoimmune hypoparathyroid-
ism, which occurs before the age of 10 years, and the second is
adrenal insufficiency, which usually develops before the age
of 15 years [9, 18].
Additional disorders include other endocrinopathies (auto-
immune hypothyroidism, type 1 diabetes, hypergonadotropic
hypogonadism, hormonal disorders of pituitary origin), ecto-
dermal dystrophy, including tooth enamel hypoplasia, abnor-
mal development of nails, gastrointestinal diseases (chronic
atrophic gastritis, malabsorption symptoms, cholelithiasis),
autoimmune hepatitis, alopecia areata, vitiligo, sclerositis
and conjunctivitis, humoral and cellular immunity deficiency,
asplenia and anemia associated with B12 deficiency [8,
19–21].
In patients with APS1 it is necessary to perform periodical
screening for 21-hydroxylase antibodies, anti-islet cell anti-
bodies, antiparietal cell antibodies, transglutaminase antibod-
ies and vitamin B12 deficiency. Autoantibodies to the T helper
17 cells and anti-cytokines interleukin (IL)-17A, IL-17 F and
IL-22 appear in APS1 patients andmay explain their increased
susceptibility to candidal infections [22, 23].
The occurrence of several additional symptoms may be
promoted by the overlap between the initial disorders and
some effects of the therapeutic interventions. Among these
secondary symptoms, basal ganglia calcification and the al-
ready discussed nephrocalcinosis should be mentioned.
Chronic hyperphosphatemia as a primary disturbance in com-
bination with excessive calcium and supplementation of ac-
tive vitamin D analogues contributes to the ectopic calcifica-
tions in the central nervous system, most commonly in the
globus pallidus [24]. These calcifications are believed to be
primarily the direct consequence of chronically elevated phos-
phate levels and high calcium × phosphate product.
Nonetheless, additional factors explaining, among others the
brain tropism, are taken into consideration. For example, the
high serum phosphate levels may activate the inorganic phos-
phate transporter (PiT1; SLC20A1), which results in the ex-
pression of osteogenic molecules in the caudate nucleus and
gray matter of the brain [25, 26]. It is estimated that cerebral
calcifications may be present in >50 % of patients with hypo-
parathyroidism. These calcifications can remain asymptomat-
ic or lead to progressive clinical symptoms, including cogni-
tive impairment, extrapyramidal symptoms and psychosis
[27].
Consequently, because basal ganglia concretions may re-
sult from Bovertreatment^ of hypoparathyroidism, it is impor-
tant to set the therapeutic goal so as to avoid symptomatic
hypocalcemia, without constant striving for full biochemical
normalization of calcemia.
Urinary calcium excretion in APS1 may vary widely be-
tween individuals and is highly dependent on treatment, med-
ication compliance and diet. As in nephrocalcinosis of other
origins, thiazide diuretics have also been successfully applied
in APS1. Thiazide diuretics have been shown to reduce uri-
nary calcium excretion and thus reduce the formation of
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calcium deposits. Thiazides diminish renal calcium excretion
by increasing calcium reabsorption in the distal tubules and by
stimulating proximal tubular reabsorption by way of volume
control. Thiazides also reduce gastrointestinal absorption of
calcium and phosphorus. The final result of these is to pro-
mote a positive calcium balance in the body [28].
Hypokalemia is an unwanted side effect that can lead to
hypocitraturia and an unplanned increase of the urinary satu-
ration (e.g. for calcium oxalate). In addition, thiazide medica-
tion may also lead to lowering of the blood pressure [29, 30].
Auron and Alon reported the resolution of medullary
nephrocalcinosis in three children with metabolic bone disor-
ders following treatment with thiazides [29]. Tubulointerstitial
nephritis has also been mentioned as a symptom of APS1.
Kluger et al. propose regular kidney monitoring for APS1
patients as they may present with kidney injury due to the
presence of circulating antibodies against the distal part of
the nephron [31].
Compliance with Ethical Standards
Conflict of interest The authors declare that they have no conflicts of
interest.
Open Access This article is distributed under the terms of the Creative
Commons Attr ibution 4.0 International License (http: / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. De Sanctis V, Soliman A, Fiscina B (2012) Hypoparathyroidism:
from diagnosis to treatment. Curr Opin Endocrinol Diabetes Obes
19:435–442
2. Barakat AY, D’Albora JB, Martin MM, Jose PA (1977) Familial
nephrosis, nerve deafness and hypoparathyroidism. J Pediatr 91:
61–64
3. Boyce AM, Shawker TH, Hill SC, Choyke PL, Hill MC, James R,
Yovetich NA, Collins MT, Gafni RI (2013) Ultrasound is Superior
to Computed Tomography for Assessment of Medullary
Nephrocalcinosis in Hypoparathyroidism. J Clin Endocrinol
Metab 98:989–994
4. Edvardsson VO, Goldfarb DS, Lieske JC, Beara-Lasic L, Anglani
F, Milliner DS, Palsson R (2013) Hereditary causes of kidney
stones and chronic kidney disease. Pediatr Nephrol 28:1923–1942
5. Sato K, Hasegawa Y, Nakae J, Nanao K, Takahashi I, Tajima T,
Shinohara N, Fujieda K (2002) Hydrochlorothiazide effectively
reduces urinary calcium excretion in two Japanese patients with
gain-of-function mutations of the calcium-sensing receptor gene. J
Clin Endocrinol Metab 87:3068–3073
6. Winer KK, Wen Ko C, Reynolds JC, Dowdy K, Keil M, Peterson
D, Gerber LH, McGarvey C, Cutler GB Jr (2003) Long-term treat-
ment of Hypoparathyroidism: a randomized controlled study
comparing parathyroid hormone-(1–34) versus calcitriol and calci-
um. J Clin Endocrinol Metab 88:4214–4220
7. Levy I, Licht C, Daneman A, Sochett E, Harrington J (2015) The
impact of hypoparathyroidism treatment on the kidney in children:
long-term retrospective follow-up study. J Clin Endocrinol Metab
100:4106–4113
8. Ergun-Longmire B, Maclaren NK. (2016 )Autoimmune endocrine
disorders. In. Jameson JL, De Groot LJ. Endocrinology: adult and
pediatric, 7th edn. Elsevier Inc., Amsterdam New York, pp 2549–
2565.
9. Neufeld M, Blizzard RM (1980) Polyglandular autoimmune dis-
eases. In: Pinchera A, Doniach D, Fenzi GF, Baschieri L (eds)
Symposium on autoimmune aspects of endocrine disorders.
Academic Press, New York, pp 357–365
10. Peterson P, Peltonen L (2005) Autoimmune polyendocrinopathy
syndrome type 1 (APS 1) and AIRE gene: new views on molecular
basis of autoimmunity. J Autoimmun 25:49–55
11. Halonen M, Eskelin P, Myhre AG, Perheentupa J, Husebye ES,
Kämpe O, Rorsman F, Peltonen L, Ulmanen I, Partanen J (2002)
AIRE mutation and human leukocyte antigen genotypes as deter-
minants of the autoimmune polyendocrinopathy—candidiasis—ec-
todermal dystrophy phenotype. J Clin Endocrinol Metab 87:2568–
2574
12. Leonard F (1946) Chronic idiopathic hypoparathyroidism with
superimposed Addison’s disease in a child. J Clin Endocrinol 6:
493–506
13. Mathis D, Benoist C (2009) Aire. Annu Rev Immunol 27:287–312
14. Biczysko-Mokosa A, Petriczko E, Horodnicka-Józwa A,
Adamczyk T, Nurczyńska A, Dawid G, Walczak M (2009)
Autoimmune polyglandular syndrome type 1 in a 11-year-old
boy. EndokrynolPed 1:75–81
15. Stolarski B, Pronicka E, Korniszewski L, Pollak A, Kostrzewa G,
Rowińska E, Włodarski P, Skórka A, Gremida M, Krajewski P,
Ploski R (2006) Molecular background of polyendocrinopathy—
candidiasis—ectodermal dystrophy syndrome in a Polish popula-
tion: novel AIRE mutation and an estimate of disease prevalence.
Clin Genet 70:348–354
16. Betterle C, Zanchetta R (2003) Update on autoimmune
polyendocrine syndromes (APS). Acta Biomed 74:9–33
17. Lindh E, Brännström J, Jones P,Wermeling F, Hässler S, Betterle C,
Garty BZ, Stridsberg M, Herrmann B, Karlsson MCI, Winqvist O
(2013) Autoimmunity and cystatin SA1 deficiency behind chronic
mucocutaneous candidiasis in autoimmune polyendocrine syn-
drome type 1. J Autoimmun 42:1–6
18. Söderbergh A, Myhre AG, Ekwall O, Gebre-Medhin G, Hedstrand
H, Landgren E, Miettinen A, Eskelin P, Halonen M, Tuomi T,
Gustafsson J, Husebye ES, Perheentupa J, Gylling M, Manns MP,
Rorsman F, Kämpe O, Nilsson T (2004) Prevalence and clinical
associations of 10 defined autoantibodies in autoimmune
polyendocrine syndrome type I. J Clin Endocrinol Metab 89:557–
562
19. Kakleas K, Soldatou A, Karachaliou F, Karavanaki K (2015)
Associated autoimmunity in children and adolescents with type 1
diabetes mellitus (T1DM). Autoimmun Rev 14:781–797
20. Husebye ES, Anderson MS (2010) Autoimmune polyendocrine
syndromes: clues to type 1 diabetes pathogenesis. Immunity 32:
479–487
21. Dittmar M, Kahaly GJ (2003) Polyglandular autoimmune syn-
dromes: immunogenetics and long-term follow-up. J Clin
Endocrinol Metab 88:2983–2992
22. Kisand K, BøeWolff AS, Podkrajsek KT, Tserel L, LinkM, Kisand
KV, Ersvaer E, Perheentupa J, ErichsenMM,Bratanic N,Meloni A,
Cetani F, Perniola R, Ergun-Longmire B, Maclaren N, Krohn KJ,
Pura M, Schalke B, Ströbel P, Leite MI, Battelino T, Husebye ES,
Peterson P, Willcox N, Meager A (2010) Chronic mucocutaneous
612 Pediatr Nephrol (2017) 32:609–613
candidiasis in APECED or thymoma patients correlates with auto-
immunity to Th17-associated cytokines. J Exp Med 207:299–308
23. Puel A, Doffinger R, Natividad A, Chrabieh M, Barcenas-Morales
G, Picard C, Cobat A, Ouachee-Chardin M, Toulon A, Bustamante
J, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C,
McConnell V, Cant AJ, Abinun M, Polak M, Bougnères PF,
Kumararatne D, Marodi L, Nahum A, Roifman C, Blanche S,
Fischer A, Bodemer C, Abel L, Lilic D, Casanova JL (2010)
Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with
chronic mucocutaneous candidiasis and autoimmune
polyendocrine syndrome type I. J Exp Med 207:291–297
24. John DR, Suthar PP (2016) Radiological features of long-standing
hypoparathyroidism. Pol J Radiol 81:42–45
25. Goswami R, Millo T, Mishra S, Das M, Kapoor M, Tomar N, Saha
S, Roy TS, Sreenivas V (2014) Expression of osteogenic molecules
in the caudate nucleus and gray matter and their potential relevance
for basal ganglia calcification in hypoparathyroidism. J Clin
Endocrinol Metab 99:1741–1748
26. Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H,
Khan AA, Peacock M, Raffaelli M, Silva BC, Thakker RV, Vokes
T, Bouillon R. (2016) Presentation of hypoparathyroidism: etiolo-
gies and clinical features. J Clin Endocrinol Metab. doi: http://dx.
doi.org/10.1210/jc.2015-3909
27. Abraham A, Ziv I, Steinmetz A, Groshar D, Djaldetti R (2010)
Autoimmune polyendocrine syndrome type I and brain calcinosis.
Parkinsonism Relat Disord 16:101–104
28. BushinskyDA, Asplin JR (2005) Thiazides reduce brushite, but not
calcium oxalate, supersaturation, and stone formation in genetic
hypercalciuric stone-forming rats. J Am Soc Nephrol 16:417–424
29. Auron A, Alon US (2005) Resolut ion of medullary
nephrocalcinosis in children with metabolic bone disorders.
Pediatr Nephrol 20:1143–1145
30. Wieczorkiewicz-Płaza A, Sikora P, Bieniaś B, Borzęcka H, Płaza P,
Zajączkowska M (2008) Leczenie pierwszych epizodów kamicy
układu moczowego u dzieci w materiale własnym. Pol Merk Lek
24[Suppl 4]:68–70
31. Kluger N, Kataja J, Aho H, Rönn AM, Krohn K, Ranki A (2014)
Kidney involvement in autoimmune polyendocrinopathy–candidi-
asis–ectodermal dystrophy in a Finnish cohort. Nephrol Dial
Transplant 29:1750–1757
Pediatr Nephrol (2017) 32:609–613 613
